山东新华制药股份(00719.HK)：获得恩他卡朋片药品注册证书

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration certificate of Entacapone tablets, which can be used as an adjunct therapy for Parkinson's disease when standard medications are insufficient [1] Company Summary - The approved product, Entacapone tablets, is indicated for use alongside standard medications such as Levodopa/Benserazide or Levodopa/Carbidopa [1] - The indication for Entacapone includes treatment for Parkinson's disease and symptom fluctuations that are not controlled by existing therapies [1]